Some terrible things, some wonderful things, some things that are totally without meaning or context... adventures in a continuing attempt to blend in with the human race.
internalised misogyny (arguably) is the act of perpetuating or upholding the misogynistic and patriarchal systems against women and those perceived as women by someone who has also experienced those systems of oppression and is projecting the harm they have experienced onto others instead of unpacking said harm.
If you believe in any of the above bullet points, you are either a TERF or you are dangerously close to falling for TERF rhetoric, and no amount of psuedo-progressive language about âcentering menâ is gonna cover up the fact that you agree with JK Rowling on at least a few points in her crusade against trans people. And that is NOT a good look.
TIL a family in Georgia claimed to have passed down a song in an unknown language from the time of their enslavement; scientists identified the song as a genuine West African funeral song in the Mende language that had survived multiple transmissions from mother to daughter over multiple centuries (x)
In 1997 Ameliaâs daughter, Mary Moran, and other members of the Moran family were invited to Sierra Leone, West Africa, where they were welcomed in Freetown by Sierra Leoneâs President and then flown by helicopter to the countryâs interior. Â There, in the small village of Senehun Ngola, Mary and Bendu Jabati met and sang this song together for the first time. Â Years earlier, Benduâs grandmother had told her that this song, which had been passed down in her village from mother to daughter for centuries, would one day reunite her to long-lost relatives.
In addition to finding out where in Africa her ancestors were abducted into slavery, Mary Moran discovered the meaning of the Mende song: a processional hymn for the final farewell to the spirit, it was sung in Senehun Ngola by women as they prepared the body of a loved one for burial.
(The OP's link leads to a site with a recording of the song sung by both Mary Moran and her mother, Amelia)
when your mutual reblogs something with a full page of tags its like. girl (gender neutral) i am filling my mug with coffee and reading this like the morning paper. i am so interested in your thoughts on this post. i love you.
For millions of people managing type 2 diabetes, mornings begin the same way â a needle, a dose, and a quiet mental note to do it all again
"For millions of people managing type 2 diabetes, mornings begin the same way â a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual â the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help â this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...
The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.
Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patientâs health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront oneâs own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a personâs life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time."
today's reason I fucking love the open source community: Ageless Linux, a brand new Debian-based operating system specifically designed to break the law by giving children access to computers that explicitly refuse to track their age.
nimble, a border collie-papillon mix, wins the 12â class in the 2024 masters agility championship. the first time a mixed breed has won at westminster ever.
